Adams Diversified Equity Fund Inc. bought a new stake in shares of Haemonetics Co. (NYSE:HAE) in the third quarter, HoldingsChannel reports. The institutional investor bought 6,700 shares of the medical instruments supplier’s stock, valued at approximately $768,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Welch & Forbes LLC bought a new position in shares of Haemonetics during the 3rd quarter valued at approximately $229,000. Oakbrook Investments LLC bought a new position in shares of Haemonetics during the 3rd quarter valued at approximately $229,000. Wealth Alliance Advisory Group LLC bought a new position in shares of Haemonetics during the 3rd quarter valued at approximately $229,000. Arjuna Capital bought a new position in shares of Haemonetics during the 2nd quarter valued at approximately $224,000. Finally, Wagner Bowman Management Corp bought a new position in shares of Haemonetics during the 2nd quarter valued at approximately $224,000. Hedge funds and other institutional investors own 95.85% of the company’s stock.
A number of research analysts have recently commented on HAE shares. TheStreet downgraded Haemonetics from a “b” rating to a “c+” rating in a research report on Monday, August 20th. Barrington Research reiterated a “buy” rating and set a $127.00 target price on shares of Haemonetics in a research report on Friday, October 5th. Morgan Stanley increased their target price on Haemonetics from $100.00 to $120.00 and gave the company an “overweight” rating in a research report on Wednesday, August 8th. Jefferies Financial Group reiterated a “buy” rating and set a $125.00 target price on shares of Haemonetics in a research report on Tuesday, August 7th. Finally, Zacks Investment Research upgraded Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 target price for the company in a research report on Friday, October 12th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $102.67.
Shares of HAE opened at $100.62 on Tuesday. The firm has a market capitalization of $5.34 billion, a P/E ratio of 53.81, a P/E/G ratio of 3.36 and a beta of 1.02. Haemonetics Co. has a 52-week low of $46.25 and a 52-week high of $117.56. The company has a quick ratio of 1.94, a current ratio of 2.84 and a debt-to-equity ratio of 0.49.
Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Tuesday, August 7th. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.17. The company had revenue of $229.35 million during the quarter, compared to the consensus estimate of $219.52 million. Haemonetics had a return on equity of 15.00% and a net margin of 2.45%. On average, sell-side analysts anticipate that Haemonetics Co. will post 2.28 earnings per share for the current fiscal year.
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Read More: Balanced Fund
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.